Jilin Jian Yisheng Pharmaceutical Co., Ltd. (SHE:002566)

SHE:002566 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	86.16	63.55	71.48	487.73	343.26	219.7
Short-Term Investments	-	-	-	-	-	30.08
Trading Asset Securities	538.4	507.57	459.67	102.98	59.84	70.16
Cash & Short-Term Investments	624.56	571.13	531.15	590.72	403.11	319.94
Cash Growth	12.23%	7.53%	-10.08%	46.54%	25.99%	11.48%
Accounts Receivable	213.74	214.89	199.03	198.53	264	254.84
Other Receivables	19.12	14.76	10.53	11.75	22.23	39.61
Receivables	232.86	230.96	209.56	210.28	286.23	294.45
Inventory	1,572	1,581	1,626	1,617	1,603	1,597
Other Current Assets	19.49	14.7	8.58	13.32	10.17	10.53
Total Current Assets	2,449	2,398	2,376	2,431	2,303	2,222
Property, Plant & Equipment	401.55	417.13	450.34	483.66	526.11	501.49
Long-Term Investments	-	15.6	15.23	-	-	-
Goodwill	1.91	1.91	1.91	1.91	1.91	1.91
Other Intangible Assets	107.32	108.66	111.35	114.18	117.03	119.96
Long-Term Deferred Tax Assets	16.98	15.85	13.15	12.62	14.2	15.2
Long-Term Deferred Charges	1.22	1.54	2.15	2.02	3.07	2.99
Other Long-Term Assets	16.55	1.13	0.76	1.27	1.68	1.04
Total Assets	2,994	2,960	2,971	3,047	2,967	2,864

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	13.56	11.69	13	24.86	24.33	19.81
Accrued Expenses	9.77	22.41	22.26	32.51	30.68	48.11
Short-Term Debt	328.22	308.23	290.28	470.43	430.43	397.86
Current Portion of Long-Term Debt	3.46	0.3	0.42	-	-	2.55
Current Portion of Leases	-	2.4	2.98	2.34	3.29	3.31
Current Income Taxes Payable	10.29	0.14	0.01	2.78	0.64	5.55
Current Unearned Revenue	9.82	14.77	5.49	11.01	24.51	16.72
Other Current Liabilities	47.06	24.17	31.55	45.91	74.29	39.84
Total Current Liabilities	422.17	384.1	366	589.85	588.16	533.75
Long-Term Debt	129.6	129.7	149.7	-	-	-
Long-Term Leases	4.25	5.34	6.21	4.03	9.82	11.46
Long-Term Unearned Revenue	105.19	108.87	112.54	118.69	118.02	120.85
Long-Term Deferred Tax Liabilities	2.36	2.34	2.77	1.74	1.17	0.02
Total Liabilities	663.56	630.35	637.22	714.3	717.18	666.08

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	330.95	330.95	330.95	330.95	330.95	330.95
Additional Paid-In Capital	834.69	834.69	834.69	834.69	834.69	834.69
Retained Earnings	1,066	1,066	1,070	1,068	989.34	916.17
Total Common Equity	2,232	2,232	2,236	2,233	2,155	2,082
Minority Interest	98.76	97.76	97.83	99.26	94.45	116.47
Shareholders' Equity	2,331	2,329	2,333	2,332	2,249	2,198
Total Liabilities & Equity	2,994	2,960	2,971	3,047	2,967	2,864

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	465.52	445.97	449.59	476.8	443.55	415.18
Net Cash (Debt)	159.03	125.16	81.56	113.92	-40.44	-95.24
Net Cash Growth	131.91%	53.45%	-28.40%	-	-	-
Net Cash Per Share	0.48	0.38	0.25	0.34	-0.12	-0.29
Filing Date Shares Outstanding	330.85	330.95	330.95	330.95	330.95	330.95
Total Common Shares Outstanding	330.85	330.95	330.95	330.95	330.95	330.95
Working Capital	2,026	2,014	2,010	1,841	1,714	1,688
Book Value Per Share	6.75	6.74	6.76	6.75	6.51	6.29
Tangible Book Value	2,123	2,121	2,122	2,117	2,036	1,960
Tangible Book Value Per Share	6.42	6.41	6.41	6.40	6.15	5.92
Buildings	-	548.36	548.14	548.14	545.7	400.71
Machinery	-	352.2	353.49	359	357.13	321.57
Construction In Progress	-	-	-	-	1.98	119.32

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error